LTFU Study of Subjects Who Received GRNOPC1

NCT05919563 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2024-08-21

No results posted yet for this study

Summary

This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.

Conditions

  • Spinal Cord Injuries

Interventions

DIAGNOSTIC_TEST

Magnetic Resonance Imaging (MRI)

Observational study; annual MRI for first 5 years only to monitor changes in the injection site

Sponsors & Collaborators

  • Lineage Cell Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Hogge, DVM, MS, PhD · Lineage Cell Therapeutics, Inc.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-06
Primary Completion
2026-12-12
Completion
2026-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05919563 on ClinicalTrials.gov